| Literature DB >> 29456814 |
Zulfiqar Ali Mirani1, Muhammad Naseem Khan1, Anila Siddiqui1, Fouzia Khan2, Mubashir Aziz3, Shagufta Naz1, Ayaz Ahmed4, Seema Ismat Khan1.
Abstract
OBJECTIVES: Staphylococcus aureus is a Gram-positive pathogen, well known for its resistance and versatile lifestyle. Under unfavourable conditions, it adapts biofilm mode of growth. For staphylococcal biofilm formation, production of extracellular polymeric substances (EPS) is a pre-requisite, which is regulated by ica operon-encoded enzymes. This study was designed to know the impact of ascorbic acid on biofilm formation and colony spreading processes of S. aureus and MRSA.Entities:
Keywords: Ascorbic acid; Biofilms; Colony spreading; Methicillin-resistant S. aureus; Staphylococcus aureus
Year: 2018 PMID: 29456814 PMCID: PMC5811756 DOI: 10.22038/IJBMS.2018.20714.5398
Source DB: PubMed Journal: Iran J Basic Med Sci ISSN: 2008-3866 Impact factor: 2.699
Biofilm formation and impact of oxacillin (Oxa) and ascorbic acid (AA) on biofilm formation properties of subject isolates of MRSA, SCCmecA and agr typing of MRSA
| Isolate No | Agr type | Biofilm OD at sub-MIC of oxacillin | Biofilm OD after treatment at 48 hr | Recovery of viable population (CFU) after biofilm treatment at 48 hr | Oxacillin MIC in µg/ml | Ascorbic acid MIC in µg/ml | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24 H | 48 H | AA | AA+ Oxa | Oxa | Control | AA | AA+ Oxa | QOxa | 24 H | 48 H | 24 H | 48 H | |||
| 1. | IV | II | 0.09 | 0.96 | 0.07 | 0.13 | 0.25 | 110±5 | 17 | 19 | 54 | 64 | 128 | 04 | 16 |
| 2. | IV | II | 0.08 | 0.92 | 0.11 | 0.13 | 0.26 | 085±5 | 22 | 15 | 47 | 64 | 128 | 04 | 08 |
| 3. | IV | II | 0.23 | 0.89 | 0.19 | 0.16 | 0.34 | 101±5 | 33 | 25 | 44 | 64 | 128 | 08 | 32 |
| 4. | IV | II | 0.27 | 0.73 | 0.32 | 0.34 | 0.42 | 129±5 | 12 | 16 | 42 | 64 | 128 | 08 | 32 |
| 5. | IV | II | 0.17 | 0.86 | 0.25 | 0.22 | 0.33 | 077±5 | 19 | 16 | 47 | 32 | 128 | 16 | 32 |
| 6. | IV | II | 0.21 | 0.80 | 0.26 | 0.24 | 0.44 | 103±5 | 27 | 33 | 63 | 32 | 128 | 16 | 32 |
| 7. | IV | II | 0.22 | 0.79 | 0.11 | 0.14 | 0.32 | 156±5 | 09 | 12 | 78 | 32 | 128 | 16 | 32 |
| 8. | IV | II | 0.35 | 0.76 | 0.54 | 0.49 | 0.55 | 177±5 | 25 | 25 | 89 | 32 | 128 | 16 | 32 |
| 9. | IV | II | 0.33 | 0.75 | 0.51 | 0.53 | 0.61 | 180±5 | 14 | 26 | 66 | 32 | 128 | 16 | 32 |
| 10. | IV | II | 0.55 | 0.87 | 0.45 | 0.47 | 0.45 | 099±5 | 12 | 07 | 57 | 16 | 128 | 16 | 32 |
| 11. | IV | II | 0.54 | 0.81 | 0.36 | 0.33 | 0.39 | 087±5 | 08 | 13 | 63 | 16 | 64 | 08 | 16 |
| 12. | IV | II | 0.55 | 0.86 | 0.31 | 0.30 | 0.44 | 097±5 | 15 | 19 | 45 | 08 | 64 | 04 | 32 |
| 13. | IV | II | 0.25 | 0.81 | 0.33 | 0.31 | 0.43 | 093±5 | 19 | 11 | 43 | 08 | 64 | 04 | 32 |
| 14. | IV | II | 0.09 | 0.85 | 0.22 | 0.26 | 0.33 | 098±5 | 13 | 17 | 43 | 64 | 192 | 32 | 64 |
| 15. | IV | II | 0.08 | 0.97 | 0.31 | 0.34 | 0.51 | 107±5 | 18 | 14 | 69 | 64 | 256 | 16 | 32 |
| 16. | IV | II | 0.23 | 0.82 | 0.19 | 0.16 | 0.49 | 136±5 | 26 | 32 | 77 | 32 | 256 | 08 | 16 |
| 17. | IV | II | 0.27 | 0.79 | 0.22 | 0.22 | 0.39 | 132±5 | 18 | 15 | 83 | 32 | 256 | 08 | 16 |
| 18. | IV | II | 0.17 | 0.81 | 0.33 | 0.35 | 0.22 | 119±5 | 25 | 19 | 54 | 16 | 128 | 08 | 16 |
| 19. | IV | II | 0.21 | 0.83 | 0.16 | 0.18 | 0.36 | 127±5 | 27 | 23 | 67 | 08 | 64 | 04 | 32 |
| 20. | IV | II | 0.22 | 0.76 | 0.34 | 0.39 | 0.44 | 098±5 | 33 | 21 | 52 | 08 | 128 | 04 | 32 |
Figure 2Scanning electron micrographs of biofilm consortia (A) after exposure to sub-inhibitory concentration of oxacillin isolate (n8) produced EPS and adapted biofilm mode of growth. (B) Cells devoid of EPS in the presence of 1 mg/ml ascorbic acid. (C) Multicellular aggregates of biofilms (isolate n8) embedded in EPS after exposure to sub-inhibitory concentration of oxacillin (D) Control growth on TSA plate
Figure 1Colony spreading and biofilm formation on congo-red agar. (A) Biofilm formation and EPS production in the presence of oxacillin on congo-red agar plate. (B) Control i.e. congo-red and tryptone soya agar plate without any supplement. (C) Colony spreading without EPS production on congo-red agar plate supplemented with sub-inhibitory dose of ascorbic acid. (D) Colony spreading without EPS production on congo-red agar plate supplemented with sub-inhibitory doses of ascorbic acid and oxacillin
Figure 3agar gene expression of MRSA after expoure to sub-inhibitory doses of ascorbic acid (AA), Oxacillin (Oxa) and oxacillin+ascorbic acid (AA+Oxa)
Figure 4icaA gene expression in MRSA isolates after expoure to sub-inhibitory doses of ascorbic acid (AA), Oxacillin (Oxa) and oxacillin+ascorbic acid (AA+Oxa)